IL2 and hepatocellular carcinoma: A recombinant NDV expressing soluble IL-2 has been shown to effectively regress hepatocellular carcinoma in mice and lead to the establishment of strong immunity that completely protected the cured mice from future challenge with cancerous cells [139].